Calquence (acalabrutinib)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved November 2017

Specific Treatments:

Mantle cell lymphoma

Therapeutic Areas

Find Related Trials for The Following Conditions

General Information

Calquence (acalabrutinib) is a small molecule Bruton tyrosine kinase inhibitor. 

Calquence is specifically indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

Calquence is supplied as a capsule for oral administration. The recommended dose is 100 mg orally approximately every twelve hours. The capsule should be swallowed whole with water and with or without food.

Clinical Results

FDA Approval

Calquence was granted accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. A phase II open label study enrolled a total of 124 patients with MCL who had received at least one prior therapy. Calquence was administered orally at 100 mg twice daily until disease progression or unacceptable toxicity. Tumor response was assessed according to the Lugano Classification for Non-Hodgkin’s lymphoma (NHL). The major efficacy outcome of the trial was overall response rate (ORR) and the median follow-up was 15.2 months. The ORR was achieved by 81% and 40% showed a Complete Response.

Side Effects

Adverse effects associated with the use of Calquence my include, but are not limited to, the following:

  • anemia
  • thrombocytopenia
  • headache
  • neutropenia
  • diarrhea
  • fatigue
  • myalgia
  • bruising

Mechanism of Action

Calquence (acalabrutinib) is a small molecule Bruton tyrosine kinase inhibitor. Acalabrutinib and its active metabolite, ACP-5862, form a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. 

Additional Information

For additional information regarding Calquence or mantle cell lymphoma, please visit